

UnitedHealthcare® Community Plan *Medical Benefit Drug Policy*

Factor Mimetics and Rebalancing Agents for Hemophilia (for Ohio Only)

Policy Number: CSOH2025D0047.B **Effective Date**: November 1, 2025

Instructions for Use

Table of Contents	Page
Application	1
Coverage Rationale	1
Policy History/Revision Information	
Instructions for Use	1

Related Policies
None

Application

This Medical Benefit Drug Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

Coverage Rationale

This policy refers to the following factor mimetics and rebalancing agents for hemophilia:

- Alhemo® (concizumab-mtci)
- Hemlibra® (emicizumab-kxwh)
- Hympavzi[™] (marstacimab-hncq)
- Qfitlia[™] (fitusiran)

Factor mimetics and rebalancing agents for hemophilia are considered medically necessary in certain circumstances. For medical necessity clinical coverage criteria, refer to the Ohio Department of Medicaid Unified Preferred Drug List Criteria.

Policy History/Revision Information

Date	Summary of Changes
11/01/2025	 Coverage Rationale Revised list of applicable factor mimetics and rebalancing agents for hemophilia; added Qfitlia[™] (fitusiran)
	Supporting InformationArchived previous policy version CSOH2025D0047.A

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state (Ohio Administrative Code [OAC]), or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state (OAC), or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state (OAC), or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state (OAC), or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

Factor Mimetics and Rebalancing Agents for Hemophilia (for Ohio Only) UnitedHealthcare Community Plan Medical Benefit Drug Policy Page 1 of 2

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.